Get the Stockscreener App
3.54
0.28%
0.01
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.54, with a volume of 2.83M.
It is up +0.28% in the last 24 hours and down -15.71% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.53
Open:
$3.51
24h Volume:
2.83M
Relative Volume:
0.52
Market Cap:
$312.43M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.1585
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-2.48%
1M Performance:
-15.71%
6M Performance:
-44.95%
1Y Performance:
-47.63%
1-Day Range:
$3.51
$3.6582
1-Week Range:
$3.51
$3.78
52-Week Range:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.54 | 314.20M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc. - PR Newswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Altimmune Inc. stock volume spike explainedJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Will Altimmune Inc. continue its uptrend2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Real time breakdown of Altimmune Inc. stock performanceEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Using Python tools to backtest Altimmune Inc. strategiesJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Is Altimmune Inc. still worth holding after the dipJuly 2025 Technicals & Verified Swing Trading Watchlists - Newser
Top chart patterns to watch in Altimmune Inc.Dollar Strength & Verified Chart Pattern Trade Signals - Newser
Altimmune, Inc. Sued for Securities Law Violations - GlobeNewswire
Altimmune wins FDA fast track status for alcohol use disorder therapy - MSN
Will Altimmune Inc. stock recover after recent dropQuarterly Market Summary & Precise Trade Entry Recommendations - Newser
Altimmune Inc (ALT) Stock: A Comprehensive 52-Week Review - investchronicle.com
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Altimmune (ALT) Gains FDA Fast Track for Alcohol Use Disorder Treatment - GuruFocus
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - WV News
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) | ALT Stock News - GuruFocus
Altimmune's Pemvidutide Receives FDA Fast Track Designation for Alcohol Use Disorder Treatment - Quiver Quantitative
28M Patient Market: Altimmune's Novel Drug Gets FDA Fast Track for Alcohol Use Disorder Treatment Gap - Stock Titan
Trend analysis for Altimmune Inc. this weekMarket Activity Recap & Scalable Portfolio Growth Ideas - Newser
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Before October 6, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel - GlobeNewswire
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights - PR Newswire
ALT LAWSUIT ALERT: The Gross Law Firm Notifies Altimmune, - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. LawsuitALT - PR Newswire
Altimmune Inc. stock trend outlook and recovery pathWeekly Trend Report & Low Drawdown Investment Strategies - Newser
Using Bollinger Bands to evaluate Altimmune Inc.Market Activity Report & Expert-Curated Trade Recommendations - Newser
Levi & Korsinsky Urges Altimmune, Inc. (ALT) Shareholders to Act Before Lead Plaintiff Deadline October 6, 2025 - ACCESS Newswire
How to interpret RSI for Altimmune Inc. stockJuly 2025 Patterns & Capital Efficiency Focused Ideas - Newser
Class Action Filed Against Altimmune, Inc. (ALT) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
Will Altimmune Inc. benefit from geopolitical trends2025 Growth vs Value & Daily Price Action Insights - newsyoung.net
Altimmune's Legal Storm: Navigating Risk and Opportunity in a Biotech Bet - AInvest
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Securities Class Action Risks in Biotech: Altimmune's Trial Drama and the Investor Sentiment Paradox - AInvest
What makes Altimmune Inc. stock price move sharplyGDP Growth & Verified Momentum Watchlists - mustnews.co.kr
Securities Fraud and Market Volatility in Biotech: Lessons from Altimmune's Collapse - AInvest
HC Wainwright Has Bullish Forecast for Altimmune Q3 Earnings - Defense World
B. Riley Estimates Altimmune’s Q3 Earnings (NASDAQ:ALT) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Shareholders - NewMediaWire
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025ALT - The Malaysian Reserve
Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Eastern Progress
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your RightsALT - Morningstar
ALT Stock News: Altimmune, Inc. Stockholder Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Altimmune, Inc. - Morningstar
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):